reports
- MarketLine Department
Flughafen Zurich AG - Company Profile and SWOT Analysis
Summary Flughafen Zurich AG - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Flughafen Zurich AG (Flughafen Zurich) is an operator of national and international airports. It operates commercial centers in landside and airside areas. It mainly operates the Zurich Airport in S...
Extraordinary General Meeting of Kinarus Holding approved all resoluti...
Kinarus Therapeutics Holding AG / Key word(s): AGMEGM Extraordinary General Meeting of Kinarus Holding approved all resolutions relating to the envisaged Business Combination with Curatis 01.03.2024 / 18:36 CET/CEST MEDIA RELEASE Basel, Switzerland, 1 March 2024: Kinarus Therapeutics Holding AG (SIX:KNRS) (“Kinarus Holding”, “KNRS” or the “Company”), a SIX Swiss Exchange listed therapeutic drug development company announced today that at the Extraordinary General Meeting of Kinarus Holding held on Friday, 1 March 2024, the shareholders of Kinarus Holding have approved with ...
- Sean Conroy
Kinarus Therapeutics - Termination of coverage
Edison Investment Research is terminating coverage on Kinarus Therapeutics (KNRS), Numis Corporation (NUM), EMIS Group (EMIS), Pixium Vision (PIX) and Treatt (TET). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via website
Kinarus Therapeutics Announces Personnel Changes
Kinarus Therapeutics Holding AG / Key word(s): Personnel Kinarus Therapeutics Announces Personnel Changes 12.07.2023 / 07:00 CET/CEST MEDIA RELEASE Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities. Dr Hari Kumar, Chairman of the Board of Kinarus Therapeutics Holding AG, com...
Kinarus Therapeutics Announces Personnel Change
Kinarus Therapeutics Announces Personnel Change Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities. Dr Hari Kumar, Chairman of the Board of Kinarus Therapeutics Holding AG, commented: “We would like to thank Subhasis for his invaluable support of Kinarus while we navigated the company thr...
Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2...
Kinarus Therapeutics Holding AG / Key word(s): AGMEGM Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting 29.06.2023 / 18:00 CET/CEST MEDIA RELEASE Basel, Switzerland, 29 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announces that its shareholders have approved all proposals by the Board of Directors at the 2023 Annual General Meeting ("AGM"), held yesterday at the ...
Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2...
Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting Basel, Switzerland, 29 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announces that its shareholders have approved all proposals by the Board of Directors at the 2023 Annual General Meeting ("AGM"), held yesterday at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland. In total, 298’358’348 shares equalling ...
Kinarus Therapeutics signed subordinated bridge loans to ensure furthe...
Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity Basel, Switzerland, June 26, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today announced the signing of subordinated bridge loan agreements with existing shareholders to ensure further liquidity is available to Kinarus during the period of time required for bridging the pending transfer of funds pursuant to a CHF1.5 million convertible loan investment from ChaoDian (...
Kinarus Therapeutics Publishes Invitation to the 2023 Annual General M...
Kinarus Therapeutics Holding AG / Key word(s): AGMEGM Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting 02.06.2023 / 08:00 CET/CEST MEDIA RELEASE Basel, Switzerland, 2 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today published the invitation to the 2023 Annual General Meeting ("AGM"), which will be held at 10 a.m. CEST on Wednesday, June 28, 2023 at the Radisson Blu Hotel Basel, St...
Kinarus Therapeutics Publishes Invitation to the 2023 Annual General M...
Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting Basel, Switzerland, 2 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today published the invitation to the 2023 Annual General Meeting ("AGM"), which will be held at 10 a.m. CEST on Wednesday, June 28, 2023 at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland. For information on the agenda items and proposals of the board of d...
Kinarus Therapeutics Group Reports 2022 Annual Results
Kinarus Therapeutics Group Reports 2022 Annual Results Publishes Annual Report with Audited Consolidated Financial Results for Year Ended 31 December 2022Clinical efforts re-focused on developing KIN001 for original indications IPF and wet AMDCDIM CHF1.5 million convertible loan agreement supports Chinese partnering Basel, Switzerland, 31 May 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today published the Annual Report with full year audited co...
- Sean Conroy
Kinarus Therapeutics - Kinarus secures CHF1.5m financing
Kinarus has announced that it has entered into a CHF1.5m strategic convertible loan agreement with ChaoDian (Hangzhou) Investment Management, an investment company based in China. The CHF1.5m subordinated loan has a three-year fixed term and does not bear any interest, and is convertible to Kinarus shares at a fixed conversion price of CHF0.01 per share. In addition to supporting Kinarus’s financial position, the company indicates the loan agreement forms the basis for future discussions on the ...
Kinarus Therapeutics signed CHF1.5 million convertible loan agreement ...
Kinarus Therapeutics signed CHF1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management Basel, Switzerland, May 10, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today announced the signing of a strategic convertible loan agreement for a CHF 1.5 million investment by ChaoDian (Hangzhou) Investment Management Co., Ltd., an investment company based in Hangzhou City, China (“CDIM”). Further, this agreement forms the basis f...
Kinarus Therapeutics Reports Key Unaudited Full Year 2022 Figures
Kinarus Therapeutics Reports Key Unaudited Full Year 2022 Figures Audited full year 2022 annual financial figures due to be reported by end of May 2023 Basel, Switzerland, May 5, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today reported unaudited key financial figures for the year ended 31 December 2022 of Kinarus Therapeutics Group. The audited full year 2022 financial figures are due to be reported by end of May 2023 On 28 April 2023, Kinaru...
Kinarus Therapeutics Holding AG ("Kinarus") receives deadline extensio...
Kinarus Therapeutics Holding AG ("Kinarus") receives deadline extension from SER for publication of its 2022 annual financial report Ad hoc announcement pursuant to Art. 53 LR Kinarus Therapeutics Holding AG ("Kinarus") receives deadline extension from SER for publication of its 2022 annual financial report Basel, Switzerland, 28 April 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases announced that on 27 April 2023 SIX Exchange Regulation ("SER") appr...
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress ...
Kinarus Therapeutics Holding AG / Key word(s): Research Update/Study Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update 21.02.2023 / 07:00 CET/CEST MEDIA RELEASE KINFAST is evaluating KIN001 for reduction in severity and duration of Covid-19 symptoms KINFAST is actively enrolling in Germany/Switzerland Basel, Switzerland, 20 February 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, provided an update today o...
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress ...
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update KINFAST is evaluating KIN001 for reduction in severity and duration of Covid-19 symptomsKINFAST is actively enrolling in Germany/Switzerland Basel, Switzerland, 20 February 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, provided an update today on progress of its Phase 2 KINFAST trial of KIN001 in Covid-19. “We’re pleased with the progress of KINFAST to date,” said Thierr...
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Dis...
Kinarus Therapeutics Holding AG / Key word(s): Research Update/Study results Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan 17.01.2023 / 07:00 CET/CEST MEDIA RELEASE KIN001 reduced fibrotic damage of the lung in a preclinical fibrosis model Potential as an effective oral therapy for Idiopathic Pulmonary Fibrosis (IPF) Phase 2 clinical trial in IPF patients in preparation Basel, Switzerland, January 17, 2023. Kinarus Therapeutics AG (SIX:KNRS) “Kinarus”, a Swiss clinical-stage biopharmaceutical company announced toda...
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Dis...
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan KIN001 reduced fibrotic damage of the lung in a preclinical fibrosis modelPotential as an effective oral therapy for Idiopathic Pulmonary Fibrosis (IPF)Phase 2 clinical trial in IPF patients in preparation Basel, Switzerland, January 17, 2023. Kinarus Therapeutics AG (SIX:KNRS) “Kinarus”, a Swiss clinical-stage biopharmaceutical company announced today preclinical data supporting the potential effectiveness of its lead clinical candidate, KIN001, as an oral treatment for idiopathic ...
- Sean Conroy
Kinarus Therapeutics - Antiviral activity against Omicron BA.2/BA.5
Kinarus has reported that its preclinical data on lead candidate KIN001 have shown strong antiviral efficacy against SARS-CoV-2 Omicron subvariants BA.2 and BA.5, which account for about a quarter of US COVID-19 infections. This builds on previously reported in vitro data, indicative of robust antiviral efficacy of equal potency against the original SARS-CoV-2 strain and other variants of concern, including Delta. We view this development as continued validation of KIN001’s mechanism of action ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.